Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
Sagari Bette, Danielle S Shpiner, Carlos Singer, Henry Moore Department of Neurology, Division of Parkinson’s Disease and Movement Disorders, University of Miami – Miller School of Medicine, Miami, FL, USA Abstract: Safinamide (Xadago®) is a novel medication with both d...
Main Authors: | Bette S, Shpiner DS, Singer C, Moore H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-09-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/safinamide-in-the-management-of-patients-with-parkinsonrsquos-disease--peer-reviewed-article-TCRM |
Similar Items
-
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson’s Disease
by: Abbruzzese G, et al.
Published: (2021-06-01) -
Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
by: Stocchi F, et al.
Published: (2016-02-01) -
A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
by: Javier Pagonabarraga, et al.
Published: (2020-03-01) -
SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
by: Ana Gómez-López, et al.
Published: (2021-01-01) -
Safinamide: an add-on treatment for managing Parkinson’s disease
by: Müller T
Published: (2018-04-01)